Rocket Pharmaceuticals Inc’s recently made public that its Director SOUTHWELL DAVID P unloaded Company’s shares for reported $0.24 million on Apr 15 ’24. In the deal valued at $24.05 per share,10,000 shares were sold. As a result of this transaction, SOUTHWELL DAVID P now holds 114,784 shares worth roughly $2.74 million.
Then, SOUTHWELL DAVID P sold 70,000 shares, generating $1,705,265 in total proceeds. Upon selling the shares at $24.36, the Director now owns 95,160 shares.
Before that, White Mark Andrew sold 12,532 shares. Rocket Pharmaceuticals Inc shares valued at $308,763 were divested by the insider at a price of $24.64 per share. As a result of the transaction, White Mark Andrew now holds 75,226 shares, worth roughly $1.8 million.
Goldman initiated its Rocket Pharmaceuticals Inc [RCKT] rating to a Neutral in a research note published on April 02, 2024; the price target was $39. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in late October with a ‘”an Overweight”‘ rating. Morgan Stanley began covering RCKT with “an Overweight” recommendation on February 01, 2023. Canaccord Genuity started covering the stock on November 08, 2022. It rated RCKT as “a Buy”.
Price Performance Review of RCKT
On Monday, Rocket Pharmaceuticals Inc [NASDAQ:RCKT] saw its stock jump 4.69% to $23.87. Over the last five days, the stock has lost -0.58%. Rocket Pharmaceuticals Inc shares have fallen nearly -20.35% since the year began. Nevertheless, the stocks have risen 28.68% over the past one year. While a 52-week high of $32.53 was reached on 02/27/24, a 52-week low of $14.89 was recorded on 04/19/24. SMA at 50 days reached $27.13, while 200 days put it at $23.01. A total of 0.57 million shares were traded, compared to the trading of 0.96 million shares in the previous session.
Levels Of Support And Resistance For RCKT Stock
The 24-hour chart illustrates a support level at 23.04, which if violated will result in even more drops to 22.21. On the upside, there is a resistance level at 24.45. A further resistance level may holdings at 25.03. The Relative Strength Index (RSI) on the 14-day chart is 40.30, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.98, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 60.96%. Stochastics %K at 18.50% indicates the stock is a buying.
The most recent change occurred on November 01, 2022 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $35 price target.
